Product image of Granissetrom Baxter (Granisetron) supplied by GNH India

Granissetrom Baxter

Active Ingredient:
Granisetron
Origin:
EU

Granissetrom Baxter (Granisetron)

Granissetrom Baxter is a prescription medication that contains the active ingredient granisetron, supplied as an intravenous solution (strength not specified). It belongs to the 5‑HT3 receptor antagonist class and is marketed in the European Union. Granisetron works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract, helping to prevent nausea and vomiting associated with chemotherapy and surgery or other emetogenic treatments in patients.

Manufacturer / TM Owner

Baxter Holding B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granissetrom Baxter is indicated for the prevention and treatment of nausea and vomiting in several clinical settings.

  • Chemotherapy‑induced nausea and vomiting (CINV) in adult patients receiving moderately to highly emetogenic chemotherapy.
  • Postoperative nausea and vomiting (PONV) following general anesthesia and surgical procedures.
  • Nausea and vomiting associated with radiation therapy when administered as part of a multimodal antiemetic regimen.
  • Prevention of emesis in patients receiving highly emetogenic cancer treatments where other antiemetics are insufficient.

Side Effects

The safety profile of Granisetron intravenous includes both frequent mild reactions and rare but potentially serious events.

Common

  • Headache
  • Constipation
  • Fatigue
  • Dizziness

Serious

  • Severe allergic reaction (anaphylaxis)
  • Cardiac arrhythmias, including QT interval prolongation

Precautions & Warnings

Before initiating Granissetrom Baxter, clinicians should evaluate patient-specific factors and monitor for known risks.

  • Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Use cautiously in patients with a history of cardiac conduction disorders or prolonged QT interval.
  • Evaluate renal and hepatic function, as dose adjustments may be required in severe impairment.
  • Consider potential pregnancy or lactation status; safety data are limited.
  • Monitor for signs of constipation or ileus, especially in postoperative patients.
  • Avoid concurrent use with other serotonergic agents that may increase the risk of serotonin syndrome.

Avoid Interactions

Granisetron may interact with other medications, influencing its efficacy or safety profile.

Avoid

  • Concomitant use with other 5‑HT3 receptor antagonists, which can increase the risk of cardiac toxicity.
  • Co‑administration with drugs that markedly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

  • Antidepressants or other serotonergic agents, due to a theoretical risk of serotonin syndrome.
  • CYP3A4 inhibitors or inducers, which may alter granisetron plasma concentrations.
  • Opioid analgesics, as they can also cause constipation and may compound gastrointestinal effects.

Frequently Asked Questions

Granissetrom Baxter is a prescription drug that contains granisetron, a selective 5‑HT3 receptor antagonist. It blocks serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing nausea and vomiting.

Granisetron for Granissetrom Baxter is given as an intravenous injection or infusion under the supervision of a healthcare professional, typically before chemotherapy or surgery.

It is most commonly used in adult patients undergoing moderately to highly emetogenic chemotherapy or those who have undergone surgery and are at risk for postoperative nausea and vomiting.

Common side effects include headache, constipation, fatigue, and dizziness. These are usually mild and transient.

Serious reactions such as severe allergic responses (anaphylaxis) or cardiac arrhythmias, including QT interval prolongation, should be reported immediately to a healthcare provider.

Safety data for Granisetron in pregnancy and lactation are limited; it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

The product should be stored at controlled room temperature, protected from light, and kept in its original packaging until administered.

Avoid using it together with other 5‑HT3 antagonists or drugs that significantly prolong the QT interval. Use caution with serotonergic agents, CYP3A4 modulators, and opioids.

Patients with known cardiac conduction disorders or a history of QT prolongation should have ECG monitoring before and during treatment.

Granisetron is a selective 5‑HT3 antagonist with a favorable safety profile and is effective for both acute and delayed phases of chemotherapy‑induced nausea, often used alone or in combination with other antiemetic classes.

Because Granisetron is administered intravenously under medical supervision, a missed dose should be addressed by the treating clinician, who will determine whether to give the dose later or adjust the treatment plan.

Granisetron can be used as part of a multimodal regimen to prevent nausea and vomiting associated with radiation therapy, especially when the radiation is highly emetogenic.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT